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Background: AMPK activation improves glucose tolerance and insulin sensitivity.
Results: Emodin increases glucose uptake in skeletal muscle and lowers blood glucose levels via AMPK activation.
Conclusion: Administration of emodin leads to increased glucose tolerance and insulin sensitivity in vivo.
Significance:Our results highlight the potential value of emodin as a drug for the treatment of diabetes.
AMP-activated protein kinase has been described as a key sig-
naling protein that can regulate energy homeostasis. Here, we
aimed to characterize novel AMP-activated kinase (AMPK)-ac-
tivating compounds that have amuch lower effective concentra-
tion than metformin. As a result, emodin, a natural anthraqui-
none derivative, was shown to stimulate AMPK activity in
skeletal muscle and liver cells. Emodin enhanced GLUT4 trans-
location and [14C]glucose uptake into themyotube in anAMPK-
dependent manner. Also, emodin inhibited glucose production
by suppressing the expression of key gluconeogenic genes, such
as phosphoenolpyruvate carboxykinase and glucose-6-phos-
phatase, in hepatocytes. Furthermore, we found that emodin
can activate AMPK by inhibiting mitochondrial respiratory
complex I activity, leading to increased reactive oxygen species
and Ca2/calmodulin-dependent protein kinase kinase activity.
Finally, we confirmed that a single dose administration of emo-
din significantly decreased the fasting plasma glucose levels and
improved glucose tolerance in C57Bl/6J mice. Increased insulin
sensitivity was also confirmed after daily injection of emodin for
8 days using an insulin tolerance test and insulin-stimulated
PI3K phosphorylation in wild type and high fat diet-induced
diabetic mouse models. Our study suggests that emodin regu-
lates glucose homeostasis in vivo by AMPK activation and that
this may represent a novel therapeutic principle in the treat-
ment of type 2 diabetic models.
AMPK2 is a highly conserved mammalian serine/threonine
protein kinase and acts as amaster energy sensor that is respon-
sible for regulating energy homeostasis (1, 2). These heterotri-
meric enzymes are activated under cellular stress conditions
such as starvation, exercise, oxidative damage, and hypoxia.
Liver kinase B1 (LKB1) and Ca2/calmodulin-dependent pro-
tein kinase kinase (CaMKK) are two regulatory upstream
kinases that stimulate AMPK phosphorylation (3). AMPK con-
trols whole body energy homeostasis by regulating glucose and
lipid metabolism in multiple peripheral tissues. For example,
AMPK activation by 5-aminoimidazole-4-carboxamide-1--
ribofuranoside stimulates glucose uptake via PI3K-independ-
ent GLUT4 translocation in skeletal muscle (4, 5) and inhibits
hepatic glucose production (6).
Recently, many types of AMPK activators, including cyto-
kines, drugs, and natural compounds, have been identified (3).
Among them, metformin (1,1-dimethylbiguanide hydrochlo-
ride) and thiazolidinediones are widely used for the treatment
of type 2 diabetes. The main function of metformin is to
decrease blood glucose levels by inhibiting hepatic gluconeo-
genesis and increasing glucose uptake in skeletal muscle (7).
Interestingly, the mitochondrial respiratory complex is the
common target ofmetformin, which indirectly activatesAMPK
(8). Inhibition of complex I activity can cause changes in the
cellular nucleotide ratio (9) and increase reactive oxygen spe-
cies (10), which are important intermediates to increase AMPK
activity. Despite their beneficial effects to glucose utilization,
metformin must be administered at high concentrations, and
they have adverse effects, such as gastrointestinal symptoms
and relatively rare lactic acidosis in vivo (11). Furthermore,
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some human studies have shown that the glucose-lowering
effects of metformin are secondary to reduction in hepatic glu-
coneogenesis (11–13). Thus, there is a growing demand to
identify more effective AMPK activators, which have low dos-
age and affect various metabolic organs.
In this study, we screened a drug library to identify novel
AMPK activators. As a result of this screening, emodin (1,3,8-
trihydroxy-6-methylanthraquinone), a natural active com-
pound in the herb Rheum palmatum L. was shown to stimulate
the AMPKpathway. Some previous studies have suggested that
emodin has an beneficial effect on energy metabolism, includ-
ing adipocyte differentiation (14), anti-fibrotic effect on pan-
creatic fibrosis (15), and liver (16). However, validation of the
molecularmechanism and the anti-diabetic effects of this com-
pound has not been fully examined. Here, we show that emodin
can increase glucose uptake in skeletal muscle via inhibition of
mitochondrial complex I, which then leads to activation of
AMPK. In addition, emodin inhibited hepatic gluconeogenesis
throughAMPK. Importantly, acute intravenous administration
of emodin in both wild type and high fat diet-induced diabetic
mice significantly decreased blood glucose levels associated
with increased glucose utilization in skeletal muscle and liver.
Based on the improved glucose metabolism and insulin sensi-
tivity, this compound holds great promise for eventual use a
therapeutic agent to treat type 2 diabetes.
EXPERIMENTAL PROCEDURES
Materials—5-Aminoimidazole-4-carboxamide-1--ribofu-
ranoside was purchased from Toronto Research Chemical Inc.
(Toronto, Ontario, Canada). Emodin, dichlorodihydrofluorescein
diacetate, o-phenylenediamine, resveratrol, and metformin were
purchased from Sigma, and 2-deoxy[14C]glucose was from
AmericanRadiolabeledChemicals Inc. Compound c, anAMPK
inhibitor, and SB203580, a p38MAPK inhibitor, were provided
by Merck (RY 70-100).
Cell Culture—L6myoblasts were grown in -minimal essen-
tial medium, andmouse hepatomaHepa1c1c7 cells weremain-
tained in DMEM containing 10% fetal bovine serum (FBS), 50
units of penicillin/ml, and 50 g of streptomycin/ml at 37 °C
under humidified air atmosphere containing 5%CO2. Differen-
tiation of myoblast was induced inmedium supplemented with
2% FBS within 7 days.
Immunoblotting—To prepare total cell lysates, myotube was
washed with cold PBS and then lysed in cold lysis buffer (in
mmol/liter: 40 HEPES, pH 7.5, 120 NaCl, 1 EDTA, 10 pyro-
phosphate, 10 glycerophosphate, 50 NaF, 1.5 Na3VO4, 1 PMSF,
5 MgCl2, 0.5% Triton X-100, and protease inhibitor mixture).
Transferred membrane was incubated with primary antibodies
(1:1000) overnight at 4 °C. The following were used: p-AMPK-
(Thr-172), ACC, p-Akt(Ser-473) (Cell Signaling Technology),
AMPK (Upstate), p-ACC(Ser-79) (Millipore), phosphoenolpy-
ruvate carboxykinase (Cayman), PGC1 (Abcam, UK), and
monoclonal anti-Myc antibody (Millipore Corp., Billerica,
MA).
AMPK Activity Assay—Cells were serum-fasted for 3 h and
then treated with emodin for 5min. After precipitation, AMPK
activity was evaluated as incorporation of 32P into a synthetic
SAMS peptide in kinase reaction buffer (in mmol/liter: 40
HEPES, pH 7.5, 80 NaCl, 1 DTT, 0.2 AMP, 0.2 ATP, 5 MgCl2,
0.1 SAMS, 0.25 [-32P]ATP) at 30 °C for 20 min.
Determination of 2-Deoxy[14C]glucose Uptake in Cells—
2-Deoxyglucose uptake was determined as described previ-
ously (17). Briefly, differentiated L6 cells were serum-starved
for 2 h prior to the assay. Cells were then washed twice with
Krebs-Henseleit buffer andwere stimulatedwith orwithout the
indicated agents for 60 min. Glucose uptake was measured by
incubation with 0.1 mCi/ml 2-deoxy[14C]glucose at room tem-
perature for 10 min.
Mitochondrial Complex I Activity—Cells were disrupted
with nondenaturing detergent lauryl maltoside to maintain
enzymatic activity and equilibrated with the indicated con-
centration of metformin and emodin for 10 min. Reaction
was initiated by adding the reaction substrate NADH (500
mol/liter) and ubiquinone-1 (50 mol/liter). A decrease in
340 nm absorbance was recorded over 10 min using a UV
spectrophotometer.
Fatty Acid Oxidation—Serum-fasted myotube was incu-
bated with emodin for 2 h in oxidation media (0.1% lipid-free
BSA, 100M [3H]palmitate, vaporized for 30minwithN2 gas to
saturate palmitate). After oxidation, the rest of the free fatty
acid was removed with 10% TCA precipitation. Supernatant in
a capless microtube was vaporized in a scintillation tube with
distilled water added at 50 °C for 12 h.
Mitochondrial Complex I Activity—Cells were disrupted
with nondenaturing detergent lauryl maltoside to maintain
enzymatic activity and equilibrated with the indicated con-
centration of metformin and emodin for 10 min. Reaction
was initiated by adding the reaction substrate NADH (500
mol/liter) and ubiquinone-1 (50 mol/liter). A decrease in
340 nm absorbance was recorded over 10 min using a UV
spectrophotometer.
Glucose Production Assay—Serum-fasted Hepa1c1c7 cells
were pretreated with emodin at the indicated concentration for
10min. After 18 h of stimulationwith forskolin (10mol/liter)/
dexamethasone (500 nmol/liter), the cells were treated with
emodin for an additional 3 h. Glucose production was mea-
sured in glucose and phenol red-free DMEM, containing glu-
coneogenic substrate sodium lactate (20 mmol/liter) and
sodium pyruvate (2 mmol/liter) for 8 h.
Quantitative PCR Analysis—Total RNA was isolated from
hepatocyte andmouse liver tissue using theTRIzol reagent, and
3 g of RNA was reverse-transcribed into cDNA. Quantitative
real time PCR analysis was carried out using HotStart-IT
SYBRGreen and Bio-Rad iCycler iQ. The sense and antisense
primers used in PCR are listed in Table 1. The relative quanti-
tation of mRNA was calculated by the comparative Ctmethod
after normalization to ribosomal protein L32.
[Ca2]i Changes—[Ca2]i was measured using the fura-2
AM method. Briefly, cells were grown on coverslip and loaded
with 1 mol/liter fura-2 AM in loading buffer (in mmol/liter
125NaCl, 5.9 KCl, 1.28CaCl2, 1.2MgCl2, 25 glucose, 0.1%BSA)
for 30 min. During the experiment, cells were continuously
drenched with the loading buffer. For [Ca2]i measurements
after emodin treatment, fura-2 images were recorded using an
OLYMPUS fluorescence microscope (DG4 light source), cap-
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tured by a Hamamatsu’s ImagEM electron multiplier CCD
(EMCCD) camera, and analyzed using a MetaMorph program.
Animal Experiments—All experimental procedures involv-
ing animals were approved by the POTECH Animal Use and
Care Committee. C57Bl/6J male mice (6–8 weeks old) were
kept in a 12-h light/dark cycle with free access to water. To
generate insulin resistance, mice received a high fat diet with
60% kcal fat for 10 weeks, and the body weight and blood glu-
cose levels were investigated. Emodin was dissolved in a vehicle
of 10% DMSO in saline/Tween 80. After emodin was injected
intravenously, the fasting glucose levels were measured using a
glucometer (Accu-Check Active; Roche Diagnostics) after the
indicated time. Serum insulin levels were determined using
insulin ELISA kits. For glucose tolerance test, overnight fasted
mice were injected with emodin and metformin 30 min before
intraperitoneal glucose injection (2 g/kg). Blood was collected
from the tail vein at 15, 30, 60, and 120 min, and glucose levels
were measured. For insulin tolerance test (ITT), fasted mice
were injected intraperitoneally with 0.75 units/kg body weight,
and blood glucose levels were measured at the indicated time
point after injection. The liver and skeletal muscle were imme-
diately frozen in liquid nitrogen and stored at 80 °C after
sacrifice.
Pyruvate Tolerance Test—For the pyruvate tolerance test,
mice received an intraperitoneal injection of sodium pyruvate
(2 g/kg) dissolved in saline after 16 h of fasting.
Immunohistocytochemistry—Paraffin-embedded skeletal
muscle was sectioned and incubated with F4/80 (ab6640,
Abcam) and CD11b primary antibody (555386, BD Biosci-
ences) for 4 h at RT. A biotinylated secondary antibody and
HRP-streptavidin antibodywith chromogen as a substratewere
used for detection (Vectastain kit PK-6102, 6104; Burlingame,
CA). The sections were counterstained in Harris’ hematoxylin
and eosin (H&E) staining.
Statistical Analysis—All data are expressed as means  S.E.
Statistical analysis between the two groups was performed by
unpaired two-tailed Student’s t test or one-way analysis of vari-
ance for multiple comparisons. p values of0.05 were consid-
ered significant.
RESULTS
Emodin Activates AMPK Signaling Pathway in L6Myotubes—
To identify novel metabolic regulators, we carried out screen-
ing with the available drug library (supplemental Fig. 1A), and
emodin (1,3,8-trihydroxy-6-methylanthraquinone) was identi-
fied to be a potent AMPK activator (supplemental Fig. 1,C–G).
Similar to its activators of AMPK, emodin also elevated the
phosphorylation level of AMPK and ACC in differentiated
myotubes (Fig. 1A). AMPK activation by emodin occurred in a
concentration- and time-dependent manner (Fig. 1, B and C).
To further confirm the AMPK activation status, we performed
a kinase assay with immunoprecipitated AMPK after emodin
treatment. In these experiments, we observed emodin signifi-
cantly enhancedAMPK activity (Fig. 1D). To compare the EC50
value of each known activator for AMPK phosphorylation, the
effect of different concentrations ofmetformin, resveratrol, and
emodin on AMPK activation was studied. As a result, 0.5 M
emodinwas shown to reach half-effective concentration, which
wasmuch lower thanmetformin (4mM) and resveratrol (50
M) (Fig. 1E). Finally, there was no significant change in cell
viability when cells were treated with emodin (supplemental
Fig. 1B). These data indicate that emodin activates the AMPK
pathway in myotubes at much lower concentrations than other
naturally active compounds.
Effect of Emodin on Glucose Uptake in Myotubes—Next, we
examined the effect of emodin on glucose uptake. In this anal-
ysis, we confirmed that emodin increased 2-deoxy[14C]glucose
uptake into myotubes in a concentration- and time-dependent
manner (Fig. 2, A and B). To elucidate the mechanism behind
this increase in glucose uptake, the level of surface GLUT4 was
measured after emodin (3 M) and metformin (10 mM) treat-
ment by immunofluorescent microscopy. Because the Myc
epitope is tagged at the extracellular region of GLUT4, translo-
cation can be easily measured without any subcellular fraction-
ation. Exposure of the Myc epitope at the plasma membrane
was increased by emodin (Fig. 2C), which was in agreement
with the glucose uptake results. We also used the o-phenylene-
diamine assay to accurately measure surface GLUT4, and we
observed a 1.5-fold increase at 3 M (Fig. 2D), which was com-
parable with the 10 mM metformin control.
To validate the effect of emodin on the insulin-mediated sig-
naling pathway, we assessed the effect of co-treatment with
emodin (3 M) and insulin (25 nM) on AKT activation and glu-
cose uptake. As shown in Fig. 2E, co-treatment did not interfere
with the respective signaling pathways. Finally, emodin was
shown to increase maximal insulin-stimulated glucose uptake
(Fig. 2F). Taken together, our findings suggest that emodin
increases GLUT4 translocation and glucose uptake, and co-
treatment with emodin and insulin produced additive effects
on glucose uptake through an independent pathway.
AMPK Mediates an Increase in Glucose Uptake by Emodin—
To examine the importance of AMPK in emodin-induced glu-
cose uptake, we used a selective AMPK chemical inhibitor and
dominant negativeAMPK2 virus, whichwere shown to be the
major isoform in skeletal muscle (18, 19). In these experiments,
TABLE 1
Target gene primers sequences for quantitative-PCR analysis
Gene
Primer sequence
Forward Reverse
G-6-Pase TCCTGGGACAGACACACAAG CAACTTTAATATACGCTATTGG
Pepck CTTCTCTGCCAAGGTCATCC TTTTGGGGATGGGCAC
Pgc-1 ATACCGCAAAGAGCACGAGAAG CTCAAGAGCAGCGAAAGCGTCACAG
MCP-1 AGGTGTCCCAAAGAAGCTGTA ATGTCTGGACCCATTCCTTCT
IL6 AGGCTTAATTACACATGTTCTCTGG TTATATCCAGTTTGGTAGCATCCAT
TNF- GATTTGCTATCTCATACCAGGAGAA AAGTCTAAGTACTTGGGCAGATTGA
RPL 32 TTAAGCGAAACTGGCGGAAAC TTGTTGCTCCCATAACCGATG
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emodin-induced AMPK activation and increase in glucose
uptake were completely blocked by compound C pretreatment
without any effects on insulin-mediated AKT activation and
glucose uptake (Fig. 3, A and B). These results indicate that the
AMPK pathway is involved in emodin-mediated glucose
uptake. Similar to the chemical inhibitor and knockdown
results (supplemental Fig. 2A), infection with dominant nega-
tive AMPK 2 completely inhibited AMPK phosphorylation
and glucose uptake induced by emodin, when compared with
empty control virus (Fig. 3, C and D). These findings demon-
strate that AMPK is a critical mediator of emodin-stimulated
glucose uptake in skeletal muscle.
In addition to AMPK activation, it has also been suggested
that insulin-mediated PI3K and p38 MAPK activation are
involved in glucose uptake in skeletal muscle (20, 21). However,
emodin did not activate AKT (Fig. 3E), and glucose uptake was
not inhibited in cells pretreated with LY-294002, a PI3K inhib-
itor, or SB203580, a p38 MAPK inhibitor (Fig. 3F).
Intracellular ROS andCa2Are Involved in Emodin-induced
AMPK Activation and Glucose Uptake—Emodin could not
activate AMPK directly (supplemental Fig. 3A). A previous
report suggested that emodin can increase intracellular ROS
levels in tumor cells (22). In addition, ROS has been shown to
activate AMPK through an LKB1 and CaMKK-dependent
pathway (23–25). Thus, we hypothesized that emodin-induced
activation of AMPKwas caused by ROS. First of all, emodinwas
shown to stimulate ROS production (Fig. 4A and supplemental
Fig. 3B). Next, we examined changes inmitochondrial complex
1 activity, which is major target of metformin (8), to better
understand the mechanism of ROS generation by emodin. As a
result, emodin dose-dependently suppressedNADHoxidation,
more effectively thanmetformin (Fig. 4B). As shown in Fig. 4,C
FIGURE 1. Emodin stimulates AMPK pathway in L6 myotubes. A, L6 myo-
tubeswerepreparedasdescribedunder “Experimental Procedures.” The cells
were treated with 10 mM metformin for 2 h, 100 M resveratrol for 1 h, and 5
Memodin for 5min. Cell lysateswere analyzedby immunoblotting for phos-
pho/total AMPK andACCantibodies.NT, not treated;AI, positive control. B, L6
myotubes were stimulated with 3 M emodin for an increasing amounts of
time.C, L6myotubewas stimulatedwith an increasing concentrationof emo-
din for 5 min. The levels of AMPK and ACC phosphorylation were quantified
by densitometry and normalized to the total AMPK and ACC, respectively.
D, AMPK activity was measured by SAMS peptide phosphorylation assay
using immunoprecipitated AMPK. E, concentration-effect curve of various
AMPK activators. The scales were selected so that the graphswere of roughly
comparable height with the saturation point at 100. Data represent one of
four independent experiments. Values aremeansS.E. *,p0.05, and **,p
0.01 versus untreated cells.
FIGURE 2. Increase of GLUT4 translocation and glucose uptake in
response to emodin. A, L6 myotubes were equilibrated in glucose-free
Krebs-Ringer buffer for 1 h and then incubatedwith the indicated concentra-
tions of emodin for 1 h. [14C]2-DOGuptakewasmeasured as described under
“Experimental Procedures.” B, L6 myotubes were incubated with 3 M emo-
din for 0 to 1 h, and glucose uptake was measured. C, immunofluorescent
detection of surface GLUT4 on confluent, quiescent L6 myotubes. The cells
were treated with 3M emodin for 1 h, and surface GLUT4 levels were deter-
mined. NT, not treated with emodin. D, quantitative analysis of surface
GLUT4. Exposure of GLUT4 was detected using the anti-Myc antibody and
coupled to the o-phenylenediamine assay as described under “Experimental
Procedures.” E, co-treatment with 3 M emodin and 25 nM insulin for 5 min.
AMPK phosphorylation was quantified by densitometry and normalized to
the total AMPK. Data represent one out of four independent experiments.
F, [14C]2-DOG uptakewasmeasuredwith emodin for 1 h and/or insulin for 10
minat the indicated concentration in L6myotubes. Values aremeansS.E. of
three independent experiments performed in triplicate. *, p  0.05, and
**, p 0.01 versus untreated cells.
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and D, emodin induced AMPK phosphorylation, and in vitro
kinase activity was largely inhibited by anti-oxidant N-acetyl-
cysteine. In addition, the increase in glucose uptake was also
blocked by N-acetylcysteine (Fig. 4E).
To verify which kind of upstream kinases were involved in
the emodin-induced AMPK activation, we used HeLa cells,
which do not express LKB1 protein. As shown in Fig. 4F, emo-
din-induced AMPK activation was also observed in HeLa cells,
whichmeans that emodin largely depends on the CaMKK. This
hypothesis was further confirmed with a CaMKK inhibitor,
STO-609. Pretreatment of myotubes andHeLa cells with STO-
609 decreased AMPK phosphorylation (Fig. 4F). Similarly,
emodin-induced glucose uptakewas significantly attenuated by
STO-609 (Fig. 4G). Finally, we examined change in cytoplasmic
free Ca2 concentration ([Ca2]i), which is critical for CaMKK
activation. As was observed for the signaling kinetics, an
increased Fura ratio was detected immediately, going from
0.57 0.005 to 1.02 0.03 (Fig. 4H). Taken together, our find-
ings indicate that emodin decreases mitochondrial complex I
activity and stimulates AMPK through intracellular ROS-de-
pendent Ca2-CaMKK pathway.
Emodin Affects Gluconeogenic Gene Expression and Hepatic
Glucose Production—To examine the function of emodin on
gluconeogenesis, we first checked the effect of emodin on the
AMPK signaling pathway in a mouse hepatoma cell line. Expo-
sure of mouse hepatocytes to emodin increased phosphoryla-
tion of AMPK and ACC within 5–30 min (Fig. 5A and supple-
mental Fig. 4A). To evaluate the effect of emodin on gluconeo-
genesis in hepatocytes, we measured glucose production with
or without emodin. As shown Fig. 5B and supplemen- tal Fig.
4B, we found that emodin suppressed the increased glucose
levels caused by forskolin/dexamethasone in a concentration-
dependent manner. Next, we examined the effects of emodin
on the expression of gluconeogenic genes. As shown in Fig. 5C
and supplemental Fig. 4C, increased transcript levels of impor-
tant gluconeogenic genes were largely suppressed by emodin
treatment. Finally, suppression of glucose production was also
recovered by AMPK inhibition (Fig. 5D). These results show
that emodin can suppress hepatic glucose production and glu-
coneogenic genes via stimulating AMPK activity.
EmodinDecreases BloodGlucose Concentration inWildType
Mice—To investigate glucose homeostasis and insulin sensitiv-
ity after emodin treatment in vivo, we first examined AMPK
phosphorylation in skeletal muscle and liver after intravenous
injection of emodin (1 mg/kg). When compared with vehicle,
emodin induced a significant increase in AMPK phosphoryla-
tion in both tissues, which was consistent with the in vitro
results (Fig. 6A). More importantly, a single intravenous injec-
tion of emodin (1 mg/kg) significantly decreased fasting blood
glucose levels in wild type mice at each indicated time point
(Fig. 6B). After 3 h, emodin decreased blood glucose levels by
42%, from 185  9 mg/dl (injection start point) to 106  6
mg/dl, whereas metformin (125 mg/kg) only decreased blood
glucose levels by 28%, from 168  12 to 121  6 mg/dl. The
decrease caused by administration of vehicle was 15%, from
176  14 to 149  10 mg/dl. There was no change in serum
insulin levels between vehicle and emodin injection group
(1.33  0.1 versus 1.04  0.2 ng/ml) (Fig. 6C). These results
strongly suggest that the glucose lowering effects of emodin are
mediated by AMPK-dependent and PI3K-independent
phenomena.
To further confirm the AMPK dependence in vivo, we exam-
ined the glucose-lowering effect of emodin with or without
compound c. In a previous report and our result (supplemental
Fig. 5), i.v. injection of compound c was shown to eliminate
phosphorylation of AMPK and ACC (26). In compound
FIGURE 3. Inhibition of AMPK blocks emodin induced glucose uptake.
A, after preincubationwith 5M of compound c (CC) for 30min, L6myotubes
were stimulated with 3 M emodin or 25 nM insulin for 5 min. Data represent
one of four independent experiments. B, cells were preincubated with com-
pound c and stimulated at the indicated conditions. NT, not treated with
emodin. [14C]2-DOG uptake was measured for 10 min. C, L6 myotubes
infected with either a mock or dominant negative-AMPK 2 adenovirus for
48 hwere treatedwith or without emodin. DN-AMPK2 expressionwas con-
firmed using the anti-Myc antibody. NT, not treated with any virus. D, [14C]2-
DOG uptake was measured with either a mock or DN-AMPK 2 adenovirus.
NT, not treated with emodin. E, emodin effect is independent of AKT. Cells
were stimulated for the indicated time period with emodin. The cell lysates
were analyzed by immunoblotting for phosphor-/total AMPK and AKT anti-
body. Data represent one of four independent experiments. F, L6 myotubes
were preincubated with AMPK inhibitor compound c, PI3K inhibitor LY
294002, and p38 MAPK inhibitor SB294002 for 1 h. [14C]2-DOG uptake was
measured for 10 min. Values are means S.E. of three independent experi-
ments performed in triplicate. *,p0.05, and **,p0.01 comparedbetween
two groups as indicated.
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FIGURE 4. AMPK activation and stimulation of glucose uptake is ROS-CaMKK-dependent. A, intracellular ROS generation by emodin. Cells were serum-
starved for 3hand incubatedwithemodin for the indicated times in thepresenceor absenceNAC. ROS levelsweremeasuredusingdihydrodichlorofluorescein
diacetate. Increased ROS generation was visualized by fluorescence microcopy. NT, not treated with emodin. B, effects of metformin and emodin on mito-
chondrial complex I activityweremeasured after 10min at the indicated concentrations. The relative activitywas expressed as a decrease in absorbance at 340
nm. C, after preincubating with NAC for 30min, L6 myotubes were stimulated with 10mMmetformin for 1 h and 3M emodin for 5 min. The cell lysates were
analyzed for phosphorylation-specific antibodies. Data represent one of four independent experiments. D, AMPK activity was measured by SAMS peptide
phosphorylation assay using immunoprecipitated AMPK and NAC. E, [14C]2-DOG uptake was measured for 10 min in the presence of compound c or NAC.
F, L6 myotubes and HeLa cells were stimulated with 3 M emodin for 5 min with or without CaMKK inhibitor STO-609. The cell lysates were analyzed by
immunoblotting, using phosphorylation-specific antibodies. G, L6 myotube was preincubated with CaMKK inhibitor STO-609 for 30 min and then
treated with 3 M emodin. [14C]2-DOG uptake was measured for 10 min. H, cells were loaded with Fura2-AM for 30 min and treated with emodin.
Response of single cell was recorded using a fluorescence microscope, captured by an EMCCD camera. Values are means  S.E. of three independent
experiments performed in triplicate. For the [Ca2]i measurements, 69 cells were used. *, p 0.05, and **, p 0.01 compared between two groups as
indicated.
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c-treatedmice, the blood glucose levels were much higher than
those in the emodin alone-treated group at all time points (Fig.
6D), and attenuation of the glucose-lowering effect of com-
pound c was profound at 2 h (decreased by 36% blood glucose
level from 218  16 to 140  9 mg/dl with emodin and 17%
from 214  12 to 178  11 mg/dl with compound c co-injec-
tion). Furthermore, emodin suppressed phosphoenolpyruvate
carboxykinase and glucose-6-phosphatase gene expression
(Fig. 6E). Finally, administration of emodin significantly
reduced blood glucose levels in a glucose tolerance test (Fig.
6F).
Emodin Stimulates Glucose Utilization and Increases Insulin
Sensitivity in High Fat-induced Diabetic Mice—We also evalu-
ated the acute and chronic glucose-lowering effect of emodin in
type 2 diabetic mouse models. Consistent with the wild type
results, phosphorylation of AMPK in skeletal muscle was also
significantly increased after single intravenous injection of
emodin (3mg/kg) (Fig. 7A). In addition, these effects correlated
with a decrease in fasting glucose levels, the decrease being 36%,
from 241 47 mg/dl (injection start point) to 154 28 mg/dl
(Fig. 7B).More importantly, compound c significantly inhibited
the glucose-lowering effect caused by emodin, which means
that the acute effect of emodin on blood glucose levels is largely
dependent on AMPK activity. During the glucose tolerance
tests, impaired glucose tolerance in high fat diet-induced obese
mice was markedly improved in the emodin-injected group,
and the improvement was much more distinct than that
observed in wild type mice (Fig. 7C). To examine insulin sensi-
tivity in chronic emodin-administered mice, we investigated
FIGURE 5. Emodin phosphorylates AMPK and suppresses gluconeogene-
sis in hepatocyte. A,Hepa1c1c7 cells were fasted for 12 h and treatedwith 3
M emodin for various time points. AMPK phosphorylationwas quantified by
densitometry and normalized to the total AMPK. Data represent one of four
independent experiments. ACT, actin. B, serum-fasted cells were treatedwith
emodin for 10 min and then stimulated with forskolin/dexamethasone (Fsk/
Dexa) for an additional 18 h. Glucose production was measured for 8 h as
described under “Experimental Procedures.” C, relative changes in the gluco-
neogenicmRNA levels.D, glucose production wasmeasured with or without
compound c. Values are means  S.E. of three independent experiments
performed in triplicate. *, p 0.05, and **, p 0.01 compared between two
groups as indicated. G6Pase, glucose-6-phosphatase; N.S., not significant.
FIGURE6.EmodinactivatesAMPKanddecreases fastingglucose levels in
wild type mice. A, AMPK and ACC phosphorylation in skeletal muscle and
liver ofwild typeC57Bl/6Jmicewas evaluatedafter a single intravenous injec-
tion of emodin. B, acute fasting glucose-lowering effect of emodin. Eight-
week-oldmalemice were intravenously treated withmetformin and emodin
at the indicated dose. Blood glucose levels were measured every 60 min.
C, serum insulin levels 3 h after intravenous injection of vehicle and emodin.
D, effect of AMPK inhibitor compound c in the emodin-injected groups. Mice
were pretreated with compound c (2 mg/kg) for 30 min and intravenously
treatedwith the vehicle and emodin. E,mRNA level of hepatic gluconeogenic
genes in the liverweremeasured inmice thatwere intravenously treatedwith
vehicle and emodin. F, glucose tolerance was determined 30 min after injec-
tion of 1 mg/kg emodin. Glucose (2 g/kg) was injected intraperitoneally.
Results are the means S.E. of six mice per group (n 6). Statistical analysis
conducted on fasting glucose lowering was performed using one-way anal-
ysis of variance and Tukey’s multiple comparison test. *, p 0.05, and **, p
0.01 versus vehicle treatment. #, p 0.05 versus emodin groups. G6Pase, glu-
cose-6-phosphatase; N.S., not significant.
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insulin tolerance after daily injection of emodin for 8 days. Dur-
ing this period, there was no change in food intake and body
weight (supplemental Fig. 6,A andB).Whenwe treated emodin
for 8 days, both basal blood glucose levels (Fig. 7D) and fed
insulin levels (Fig. 7E) were significantly decreased. Further-
more, insulin-mediated glucose-lowering effects in ITT were
more obvious than the vehicle group (Fig. 7F), and AKT phos-
phorylation by insulin was significantly increased in emodin-
injected mice (Fig. 7G). Finally, increased blood glucose levels
were largely attenuated in emodin-treated mice in a pyruvate
tolerance test, indicating reduced gluconeogenesis in liver (Fig.
7H). Together, our results suggest that emodin activates AMPK
in vivo, which is responsible for increased glucose tolerance and
insulin sensitivity in multiple peripheral tissues.
Diet-induced Inflammatory Cytokines and Macrophages Are
Attenuated after Emodin Administration—It has been demon-
strated that inflammatory cytokines in skeletal muscle and adi-
pose tissue are elevated in obesity (27). To elucidate the effect of
emodin onmuscle inflammatory cytokine andmacrophage lev-
els, we measured transcript levels of pro-inflammatory cyto-
kine after treatment of emodin in high fat diet-induced obese
mice. Fig. 8A and supplemental Fig. 7 indicate that the cytokine
transcript levels were largely inhibited. Furthermore, infiltra-
tion of F4/80-positive macrophages was also suppressed by
chronic treatment of emodin (Fig. 8B). These results suggest
that emodin decreases diet-induced inflammation status in the
skeletal muscle.
DISCUSSION
It has been demonstrated that emodin suppresses cell growth
and proliferation inmany types of tumor cells (22, 28, 29), and it
inhibits inflammations in vascular endothelial cells (30, 31). In
this study, we found that emodin activates AMPK by modulat-
ing mitochondrial complex I activity. Through inhibiting com-
plex I, emodin increases cellular ROS and Ca2 influx, which
are well known conditions for AMPK activation. Importantly,
the effect of emodin was much more potent than that of met-
formin and extended to muscle and liver. As an anti-tumor
agent, the required effective concentration of emodin in vivo is
FIGURE 7. Emodin improves glucose tolerance and insulin sensitivity in
high fat induced diabetic mice. A, AMPK and ACC phosphorylation in skel-
etal muscle of high fat diet-induced C57Bl/6J obese mice after a single intra-
venous injection of emodin at the indicated dose. B, effect of AMPK inhibitor
compound c in emodin-injected groups. Mice were pretreated with com-
pound c (2mg/kg) for 30min and injected intravenouslywith the vehicle and
emodin. C, blood glucose levels weremeasured after intraperitoneal glucose
injection (2 g/kg) in single i.v. administration of emodin. D and E, basal glu-
cose levels and fed insulin levels were measured after 8 days injection of
emodin. NCD, normal chow diet; HFD, high fat diet. F, ITT after daily i.v. injec-
tionof emodinandmetformin for 8days. Bloodglucose levelsweremeasured
after intraperitoneal insulin injection (0.75 units/kg). G, representative AKT
phosphorylation in skeletal muscle under basal conditions was compared
with that after insulin treatment inmice subjected to emodin i.v. injection for
8 days. H, pyruvate tolerance test after 8 days of injection of emodin. Results
are themeans S.E. of ninemice per group (n 9). For the ITT, fivemice per
group (n 5). One-way analysis of variance, Tukey’smultiple comparison test
was performed at fasting glucose lowering and glucose tolerance test. *, p
0.05, and **, p  0.01 versus vehicle treatment; #, p  0.01 versus emodin
groups. N.S., not significant.
FIGURE 8. Decreased muscle pro-inflammatory cytokines and macro-
phages. A, relativemRNA levels of inflammatory cytokines in skeletal muscle
were measured. B, representative F4/80 staining of macrophages in skeletal
muscle. Muscle sections of vehicle or emodin-treated high fat diet (HFD)-
induced obese mice were stained for the general macrophage marker F4/80
with magnification40. Magnification20 was used for the quantification
(n 10). *, p 0.05, and **, p 0.01 versus vehicle treatment.
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relatively high, and it inhibits only some types of tumors but not
nontumor cells (22, 28). The emodin concentrations (up to 5
M) used in this study does not cause cell death or apoptosis as
measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide assay. In addition, a very recent paper
showed that exposure to nearly 800mg/kg emodin for 14weeks
through the diet did not show any developmental and testicular
toxicity inwild typemice (32, 33).Hence, the low concentration
range that we have used is reasonable with regard to a potential
therapeutic treatment regimen for type 2 diabetes.
Mitochondrial complex I is the rate-limiting step of the elec-
tron transport chain. In addition to cellular respiration, the
importance of complex I as a diabetic target has been suggested.
Metformin directly inhibits complex I, which leads to an
increase in AMPK activity and insulin sensitivity (8, 34). We
have also observed that emodin decreased NADH conversion
to NAD, which means complex I activity was inhibited. This,
in combinationwith the relationship betweenAMPKandmito-
chondria, suggests that emodin increases AMPK activity by
modulating mitochondrial metabolism in skeletal muscle. One
possibility is the competitive inhibition between emodin and
ubiquinone, a membrane-embedded electron carrier (35).
Because emodin (1,3,8-trihydroxy-6-methylanthraquinone)
also belongs to the quinone family, it is possible that they have a
common binding site in the complex I subunit. Therefore, it
would beworth examining if the binding domain of ubiquinone
overlaps with that of emodin.
A recent study demonstrated that chronic treatment with
emodin lowered body weight in the diet-induced obese mouse
by suppressing 11-hydroxysteroid dehydrogenase type 1 (11-
HSD1) activity in liver and adipose tissue (36). 11-HSD1 is an
NADPH-dependent enzyme that is related to obesity and insu-
lin resistance via the glucocorticoid signal (37). This study sug-
gested that reduced food intake, by inhibition of the orexigenic
glucocorticoid signal, may partly contribute to body weight
loss. Although reduced fat mass and serum lipid contents
through the inhibitory function on 11-HSD1 in liver and adi-
pocyte tissue are important in vivo, emodin-induced AMPK
activation in skeletal muscle may be another major anti-dia-
betic mechanism. Skeletal muscle constitutes 40% of body
mass and is an essential tissue responsible for 75% of the whole
body glucose uptake to exert glucose lowering (38). Indeed, in
our study, AMPK inhibitor compound c largely attenuated glu-
cose uptake in skeletalmuscle cells, resulting inmuch less effec-
tive glucose lowering in a mouse model. In addition, emodin-
induced AMPK activation can contribute to weight loss,
because AMPK is known to increase fatty acid oxidation (39,
40) and mitochondrial biogenesis (19), which protects against
obesity (2). The data provided in this study, where AMPK was
shown to increase fatty acid oxidation and related genes, sup-
port this hypothesis (supplemental Fig. 8, A and B). In fact, a
very recent paper also reports that emodin increases AMPK
and ACC in hepatocytes and adipose tissues of high fat diet-fed
rats and improves dyslipidemia after 8 weeks of treatment (41,
42).
In contrast to chronic exposures, many reports have sug-
gested that modest ROS generation represents a favorable con-
dition for glucose utilization (43). For example, ROS can
decrease protein phosphatase activity, such as PTP1B (44) and
PTEN (45). In addition, ROS also stimulates AMPK activity in
many peripheral tissues (25, 46, 47), and it is well known that
ROS generated during exercise and muscle contraction accel-
erates glucose uptake in skeletal muscle through AMPK (48,
49).Metformin and epigallocatechin-3-gallate suppress hepatic
gluconeogenesis by ROS-mediated AMPK activation in the
liver (50). By using genetic models, many groups have demon-
strated the acute requirement of ROS for AMPK activation,
which has many beneficial metabolic effects (47, 51, 52). Based
on the significant inhibition of AMPK and glucose uptake by
NAC, we suggest that ROS generation by emodin plays an
important role in the activation AMPK. Of course, it is still
possible that othermechanisms are involved in the induction of
AMPK activity. Mitochondrial uncoupling proteins function
with ROS to produce heat without ATP generation, andwe also
observed a small but statistically significant decrease in ATP
content (Table 2). However, given the AMPK phosphorylation
in LKB1(/) cells, AMP/ATP ratio changes may take small
charge of emodin-inducedAMPK activation, because LKB1 is a
critical upstream kinase to activate AMPK under AMP-en-
riched conditions. When we consider the importance of LKB1
in actions of metformin (53), this difference would be a clue for
explaining distinct kinetics and in vivo potency between emo-
din and metformin. Furthermore, some previous results and
our experimental results suggest that the liver is themain target
tissue of metformin to show a glucose-lowering effect (11, 13).
So, when compared with metformin, emodin does not have
tissue specificity and has a comparative advantage regarding
this aspect.
Blood glucose concentration is mainly regulated by glucose
uptake in skeletal muscle and glucose production in liver. To
determine whether emodin can also activate AMPK and
decrease blood glucose in vivo, we carried out a single and pro-
longed intravenous administration of emodin in wild type and
high fat diet-induced obesemice. Remarkably, a single injection
of emodin sufficiently lowered fasting glucose levels within 3 h
in both in vivo models, and this effect was much more potent
than the effect observed in the metformin groups. Because
therewas no change in serum insulin levels between vehicle and
emodin administration, the AMPK pathway is likely the main
mechanism by which emodin regulates blood glucose levels.
Also, we observed that emodin was able to improve glucose
tolerance both in wild type and high fat diet-induced diabetic
mice, and chronic treatment increased insulin sensitivity.
In summary, we show that emodin improves glucose utiliza-
tion in wild type and diabetic mouse models. The main mech-
anisms of these glucose-lowering effects are stimulation of glu-
TABLE 2
Adenine nucleotide concentrations after emodin treatment
Effect of emodin on the intracellular AMP/ATP contents is shown. Cell lysates were
extracted with a perchloric acid and analyzed using HPLC. Values are means
S.E. of two independent experiments performed in triplicate.
Treatment AMP ATP
AMP/ATP
ratio
nmol/mg nmol/mg
Not treated 0.90 0.09 34.4 1.96 0.026 0.001
Emodin (3 M) 1.13 0.31 29.2 2.44a 0.040 0.01
a p 0.05 versus untreated cells.
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cose uptake in skeletal muscle and suppression of hepatic
gluconeogenesis via AMPK phosphorylation. Furthermore,
AMPKactivation ismediated by inhibiting the enzymatic activ-
ity of complex I of the respiratory chain. Hence, we have iden-
tified a new mechanism whereby emodin lowers plasma glu-
cose levels, which may have interesting implications for the
treatment of type 2 diabetes.
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